What Seismic Therapeutic does

Seismic Therapeutic is a clinical-stage biotechnology company developing biologic therapeutics for autoimmune, antibody-mediated, and allergic diseases using a proprietary machine learning platform. Founded in 2022 and headquartered in Watertown, Massachusetts, the company is led by Jo Viney, PhD (founder, President, and CEO), who previously founded Pandion Therapeutics (acquired by Merck for $1.85 billion in 2021), alongside scientific co-founders Timothy A. Springer, PhD (Harvard Medical School; 2022 Lasker Award recipient), Andrew Kruse, PhD (Harvard Medical School), and Debora Marks, PhD (Harvard Medical School). The company has raised approximately $247 million in venture capital across a $101M Series A (February 2022, led by Lightspeed Venture Partners), a $121M Series B (December 2023, led by Bessemer Venture Partners), and a $25M financing event in September 2024. With 51–100 employees and no commercial products, the company is currently pre-revenue.

Name

Seismic Therapeutic

Legal name

Seismic Therapeutic, Inc.

Website

https://seismictx.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

51–100 employees

Short description

Seismic Therapeutic is a clinical-stage biotechnology company using its proprietary IMPACT machine learning platform to develop biologic therapeutics for autoimmune, antibody-mediated, and allergic diseases, with two candidates in Phase 1 trials.

Ownership category

akta.pro rank

Product category

Clinical-Stage Biologics Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

akta.pro secondary industries

Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Machine learning immunology
• Biologics drug discovery
• Autoimmune therapeutics
• Antibody engineering platform
• Clinical-stage biotechnology

Headquarters

HQ city

Watertown

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Biopharmaceutical Development and Commercialization: Pre-revenue clinical-stage biotechnology company developing novel biologic therapeutics. Revenue will be generated through eventual product sales or licensing/partnership agreements with larger pharmaceutical companies upon regulatory approval.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Seismic Therapeutic is a clinical-stage biotechnology company that designs and develops biologic drug candidates for autoimmune, inflammatory, and allergic diseases using its proprietary IMPACT platform, which integrates machine learning with structural biology, protein engineering, and translational immunology. Its lead programs include S-1117 (an engineered pan-IgG protease), S-4321 (a PD-1:FcγRIIb bifunctional antibody), and S-8484 (an IgE protease), with future commercialization planned through large-pharma partnerships.

Product overview

Seismic Therapeutic is a clinical-stage, product-centric immunology company powered by its proprietary IMPACT machine learning platform. The company is creating transformative biologic medicines for autoimmune and inflammatory diseases through a pipeline of first-in-class and best-in-class programs derived from the IMPACT platform. The pipeline focuses on three therapeutic areas: (1) Multi-functional antibodies including S-4321 (PD-1:FcγRIIb bifunctional agonist antibody in Phase 1) targeting cell-mediated immune diseases; (2) Immunoglobulin Sculpting enzymes including S-1117 (pan-IgG protease in Phase 1) and S-8484 (IgE protease in IND-enabling studies) targeting antibody-mediated and allergic diseases; and (3) IgE-targeted programs for allergic diseases. The IMPACT platform enables parallelized multi-property optimization integrating machine learning with structural biology, protein engineering, and translational immunology to accelerate drug discovery.

Differentiator

Problem solved

Functional benefit

Brands

• IMPACT Platform: Proprietary machine learning platform that integrates structural biology with machine learning to design novel biologics through parallel optimization of multiple molecular attributes.

Products and services

• S-1117 (pan-IgG protease) An engineered Fc-fused pan-IgG protease designed to selectively cleave pathogenic IgG and address multiple pathogenic mechanisms in autoantibody-mediated diseases such as myasthenia gravis and immune thrombocytopenia; engineered for reduced immunogenicity and suitable for chronic dosing.
• S-4321 (PD-1:FcγRIIb bifunctional antibody) A non-depleting PD-1:FcγRIIb bifunctional agonist antibody that agonizes PD-1 on T cells and selectively engages FcγRIIb on B cells and antigen presenting cells, designed to restore immune homeostasis on both sides of the immune cell synapse for treatment of T cell-driven autoimmune diseases.
• S-8484 (IgE protease) A novel immunoglobulin E (IgE) protease engineered to selectively cleave IgE and eliminate it from circulation and cell surfaces, designed to address humoral immune dysregulation in allergic diseases such as food allergies, chronic rhinosinusitis with nasal polyps, and chronic spontaneous urticaria.

Quantifiable outcome

• Rapid advancement of two lead programs from founding to Phase 1 clinical trials in approximately 3 years
• +2 more outcomes

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• Yale UniversitycoreStrategic or Co-development Partner · 21 October 2025Multi-year collaboration with Yale University led by Kevin O'Connor, PhD, Professor of Neurology and Immunobiology at Yale School of Medicine. Collaboration focuses on research into immunoglobulin proteases and autoimmune diseases including myasthenia gravis. Results published in PNAS in 2025.
• Debora MarkscoreOthersCo-founder; Associate Professor in the Department of Systems Biology at Harvard Medical School. Develops novel algorithms and machine learning methods for protein design and biomolecular systems.
• Andrew KrusecoreOthersCo-founder; Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. Expert in structure and function of transmembrane receptors and single-domain antibody fragment discovery platform.

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Generate Biomedicines: Generate Biomedicines is the closest direct competitor — a Flagship Pioneering-backed company using generative ML to design novel protein therapeutics across multiple therapeutic areas. Both companies pursue ML-designed biologics with parallelized optimization of developability, immunogenicity, and function.
• BigHat Biosciences: BigHat Biosciences uses ML-driven antibody design and engineering with a wet-lab loop to optimize therapeutic antibodies, directly analogous to Seismic's IMPACT platform. Targets similar immunology and oncology indications and competes for pharma partnership deals in ML-designed biologics.
• AbCellera Biologics: AbCellera is a publicly traded AI/ML-enabled antibody discovery platform that partners with pharma to discover therapeutic antibodies. Comparable business model of platform-driven antibody discovery with multiple internal programs, and a directly competitive position in the AI-designed biologics space.
• AnaptysBio: AnaptysBio is a clinical-stage immunology biotech developing antibody therapeutics for autoimmune and inflammatory diseases (e.g., rosnilimab, PD-1 agonist). Direct therapeutic-area peer competing in the same autoimmune biologics market with similar mechanism classes (PD-1 agonist, IL-36R antagonist).
• Alumis: Alumis (formerly Esker Therapeutics) is a clinical-stage immunology company developing small molecules and biologics for autoimmune diseases, with a strong focus on immunology biology. Direct therapeutic-area competitor with similar indications (lupus, MS) and overlapping investor syndicate.
• Kymera Therapeutics: Kymera is a clinical-stage immunology biotech developing targeted protein degraders for autoimmune and inflammatory diseases. Therapeutic-area peer pursuing immunology with novel modality (PROTAC degraders), comparable stage and capitalization profile, and similar BD-focused strategy.
• Compass Therapeutics: Compass Therapeutics is a clinical-stage biotech developing antibody therapeutics for autoimmune diseases and oncology, with lead programs in autoimmune indications (e.g., CTX-101). Direct therapeutic-area peer at comparable stage competing for the same autoimmune biologics market.

Broad incumbents

• Adimab: Adimab is an established antibody discovery and engineering platform that pioneered yeast display-based antibody optimization — a foundational capability that Seismic's IMPACT platform builds upon with ML. Broader incumbent in antibody engineering offering platform services to pharma.

Others

• Pandion Therapeutics: Pandion Therapeutics was the prior biotech founded by Seismic's leadership team (Jo Viney, Alan Crane, Kevin Otipoby, John Sundy) focused on autoimmune biologics, acquired by Merck for $1.85B in 2021. Direct predecessor company providing the proof point for the current team's execution capability.

Emerging players

• Cradle Bio: Cradle is an emerging ML-driven protein design company applying generative AI to biologics discovery across multiple therapeutic areas. Comparable technology approach (ML for protein design) but earlier stage with broader therapeutic scope and less immunology-specific focus than Seismic.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/Seismic_Tx
• LinkedInlinkedin.com/company/seismic-therapeutic

Revenue estimate

Valuation estimate

Number of profiles

Profiles15 records

Funding overview

Funding rounds3 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Seismic Therapeutic